

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 25th January, 2019

Scrip Code: - 531768

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 25th January, 2019, at Crowne Plaza Hotels, Community Center, Okhla Phase-I, New Delhi - 110020, approved the following businesses:

- a) Un-Audited Financial Results (Standalone) for the quarter and Nine Months ended on 31st December, 2018.
- b) Other normal business.

We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You,

Yours Sincerely

For Poly Medicure Limited



Avinash Chandra
Company Secretary

POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020

Phone: 011-26321889, Fax: 011-26321894

Website: www.polymedicure.com, E-mail: Investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

		Quarter Ended			Nine Months Ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)					(Audited)
1	Income						
a	Revenue from Operations	14,870.25	14,675.06	12,574.69	42,682.06	36,933.71	50,969.93
b	Other Income	374.76	410.60	354.68	1,118.63	971.02	1,436.95
	Total Income	15,245.01	15,085.66	12,929.37	43,800.69	37,904.73	52,406.88
2	Expenses						
a	Cost of materials consumed	5,106.35	4,535.73	4,226.86	13,897.28	12,160.36	16,713.93
b	Purchases of stock-in-trade	107.39	511.49	129.40	635.50	303.51	437.26
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	85.29	(395.23)	(506.91)	(607.96)	(1,103.95)	(994.00)
d	Excise Duty on Sales	-	-	-	-	126.10	126.10
e	Employee benefits expense	2,768.34	2,677.34	2,437.34	8,047.98	6,928.09	9,392.66
f	Research and development expenses	291.51	304.73	238.95	889.58	733.01	1,004.78
g	Finance cost	(86.49)	643.91	176.14	938.43	627.72	949.51
h	Depreciation and amortisation expense	935.89	909.14	707.83	2,704.67	2,053.85	2,840.66
i	Other expenses	3,405.32	3,590.46	3,091.36	10,145.44	9,093.46	12,300.39
	Total expenses	12,613.60	12,777.57	10,500.97	36,650.92	30,922.15	42,771.29
3	Profit from operations before exceptional items (1-2)	2,631.41	2,308.09	2,428.40	7,149.77	6,982.58	9,635.59
4	Exceptional Items						
5	Profit before tax	2,631.41	2,308.09	2,428.40	7,149.77	6,982.58	9,635.59
6	Tax expense						
a	Current tax	725.86	753.44	684.12	2,175.08	2,257.49	2,536.55
b	Deferred tax	139.60	108.61	53.07	418.59	(26.82)	79.21
c	Earlier Year Taxes	82.69	-	37.65	76.02	37.65	-
	Total Tax Expense	948.15	862.05	774.84	2,669.69	2,268.32	2,615.76
7	Profit for the period	1,683.26	1,446.04	1,653.56	4,480.08	4,714.26	7,019.83
8	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss :						
	Remeasurements of defined benefit obligations	(19.91)	4.56	18.14	(5.44)	22.63	40.77
	Tax impacts on above	6.96	(1.60)	(6.28)	1.90	(7.83)	(14.11)
	Total Other Comprehensive Income	(12.95)	2.96	11.86	(3.54)	14.80	26.66
9	Total comprehensive Income (comprising profit after tax and other comprehensive Income after tax for the period)	1,670.31	1,449.00	1,665.42	4,476.54	4,729.06	7,046.49
10	Paid-up equity share capital (Face Value of ₹ 5 each)	4,411.85	4,411.85	4,411.34	4,411.85	4,411.34	4,411.34
11	Earnings per share (Quarterly not annualised) :						
	Basic (₹)	1.91	1.64	1.89	5.08	5.36	7.96
	Diluted (₹)	1.91	1.64	1.89	5.08	5.36	7.95



Murach

Notes:

- 1 The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 25th January, 2019. The Statutory auditors have conducted a limited review of the above Financial Results.
- 2 In line with the provisions of Ind AS 108 – Operating Segments and on the basis of review of operations being done by the management of the Company, the operations of the company falls under medical devices, which is considered to be the only reportable segment by the management.
- 3 Revenue for the period 01st April, 2017 to 30th June, 2017 were reported inclusive of excise duty. Accordingly, revenue for the nine months ended 31st December, 2017 includes excise duty of Rs.126.10 lacs. Revenue for subsequent periods are net of Goods and Services Tax (GST).
- 4 During the quarter ended 30th September, 2018, the Company had allotted 10050 No. of Equity shares under Employees Stock option scheme 2015 at a face vale of Rs. 5 each at an exercise price of Rs. 50 per share, however, listing of such shares and filing of necessary documents with ROC is under process.
- 5 The Company has opted to publish standalone financial results for the quarter and nine months ended 31st December, 2018. The consolidated financial results shall be published for the quarter / year ending 31st March, 2019.
- 6 The standalone unaudited financial results of the Company for the quarter and nine months ended 31st December, 2018 are also available on the Company's Website (www.polymedicure.com) and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com) in accordance with the provisions of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.
- 7 Previous period figures have been regrouped wherever necessary to conform to the current period classification.

Place : New Delhi
Date : 25.01.2019



Himanshu Baid
Managing Director



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020,

Phone: 011-26321889, Fax: 011-26321894



Website: www.polymedicure.com, E-mail: Investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

(Rs. in Lacs)

	Quarter Ended		Nine Months Ended
	31.12.2018	31.12.2017	31.12.2018
	Unaudited		
1 Total Income from operations	15,245.01	12,929.37	43,800.69
2 Net Profit for the period (before tax, exceptional and/or extraordinary items)	2,631.41	2,428.40	7,149.77
3 Net Profit for the period before tax (after exceptional and/or extraordinary items)	2,631.41	2,428.40	7,149.77
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	1,683.26	1,653.56	4,480.08
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,670.31	1,665.42	4,476.54
6 Equity paid up share capital	4,411.85	4,411.34	4,411.85
7 Earnings per share (Quarterly not annualised) :			
Basic (₹)	1.91	1.89	5.08
Diluted (₹)	1.91	1.89	5.08

- The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 25th January, 2019. The Statutory auditors have conducted a limited review of the above Financial Results.
- The above is an extract of the detailed format of standalone Quarterly and Half yearly Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited standalone Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.
- Previous period figures have been regrouped wherever necessary to conform to the current period classification.

Place : New Delhi
Date : 25.01.2019

Himanshu Baid
Managing Director



DOOGAR & ASSOCIATES

Chartered Accountants

To Board of Directors
Poly Medicare Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020


We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicare Limited ("the company") for the quarter ended 31st December, 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm Registration No. 000561N


M. S. Agarwal
Partner
Membership No. 86580



Place of signature: New Delhi
Date: 25th January 2019